Provided by Tiger Fintech (Singapore) Pte. Ltd.

Charles River Laboratories

169.28
+2.651.59%
Volume:327.07K
Turnover:54.97M
Market Cap:8.66B
PE:846.38
High:170.46
Open:168.50
Low:165.35
Close:166.63
Loading ...

Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)?

Simply Wall St.
·
27 Dec 2024

Charles River Laboratories International Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
24 Dec 2024

Year-end selling is hitting these 7 stocks. How their tax loss can be your gain.

Dow Jones
·
21 Dec 2024

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Benzinga
·
21 Dec 2024

Lexicon receives CRL for Zynquista

TIPRANKS
·
21 Dec 2024

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

GlobeNewswire
·
21 Dec 2024

Tax-related selling is hitting these 7 stocks - but their loss could be your gain

Dow Jones
·
20 Dec 2024

Charles River Laboratories International Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
20 Dec 2024

Zealand Pharma says FDA issues CRL for glepaglutide NDA

TIPRANKS
·
20 Dec 2024

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

GlobeNewswire
·
20 Dec 2024

Earnings are growing at Charles River Laboratories International (NYSE:CRL) but shareholders still don't like its prospects

Simply Wall St.
·
19 Dec 2024

Deutsche Bank Adjusts Charles River Laboratories International Price Target to $245 From $250

MT Newswires Live
·
18 Dec 2024

FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC

Zacks
·
17 Dec 2024

Morgan Stanley Trims Price Target on Charles River Laboratories International to $220 From $225, Keeps Equalweight Rating

MT Newswires Live
·
17 Dec 2024

Nyse Order Imbalance 26701.0 Shares on Sell Side

THOMSON REUTERS
·
17 Dec 2024

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

Benzinga
·
16 Dec 2024